Abstract | OBJECTIVE: DESIGN: This was a cross-sectional study. PATIENTS: We performed two-dimensional and Doppler echocardiography in 78 consecutive patients with prolactinoma (mean age 47 +/- 1.4 yr, 26% male, 31% macroprolactinoma) treated with dopamine agonists for at least 1 yr (mean 8 +/- 0.6 yr) and 78 control subjects. Patients were classified according to treatment: patients treated with cabergoline (group 1: n = 47) and patients not treated with cabergoline (group 2: n = 31). RESULTS: Clinically relevant valvular heart disease was present in 12% of patients (nine of 78) vs. 17% of controls (13 of 78) (P = 0.141) and 17% (eight of 47) of patients treated with cabergoline vs. 3% (one of 31) of patients not treated with cabergoline (P = 0.062). Mild tricuspid regurgitation was present in 41% of patients vs. 26% of controls (P = 0.042), and aortic valve calcification was present in 40% of patients, compared with 18% of controls (P = 0.003). There was no relation between the cumulative dose of cabergoline and the presence of mild, moderate, or severe valve regurgitation. CONCLUSION:
|
Authors | Marleen Kars, Victoria Delgado, Eduard R Holman, Richard A Feelders, Johannes W A Smit, Johannes A Romijn, Jeroen J Bax, Alberto M Pereira |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 93
Issue 9
Pg. 3348-56
(Sep 2008)
ISSN: 0021-972X [Print] United States |
PMID | 18559921
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Dopamine Agonists
- Ergolines
- Cabergoline
|
Topics |
- Adult
- Aortic Valve
(drug effects, pathology)
- Cabergoline
- Calcinosis
(chemically induced)
- Case-Control Studies
- Cross-Sectional Studies
- Disease Progression
- Dopamine Agonists
(adverse effects, therapeutic use)
- Ergolines
(adverse effects, therapeutic use)
- Female
- Heart Valve Diseases
(chemically induced, epidemiology)
- Humans
- Male
- Middle Aged
- Pituitary Neoplasms
(drug therapy)
- Prevalence
- Prolactinoma
(drug therapy)
- Time Factors
- Tricuspid Valve Insufficiency
(chemically induced)
|